Low-dose dihydroartemisinin resensitizes lung cancer cells to cisplatin, suggesting a new combination strategy for treatment.
At clinically relevant concentrations, the principal antitumor property of DHA lies in TME modulation rather than direct cytotoxicity. By inhibiting macrophage-derived IL-6, DHA simultaneously mitigated chemoresistance and invasion, resensitizing lung cancer cells to cisplatin. These findings provide a mechanistic rationale for combining DHA with platinum-based chemotherapy.
No takes yet. Share an insight, caveat, or question.
Ruan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: